Vertex Pharmaceuticals remains the leader in cystic fibrosis but is now executing a tangible diversification into pain, renal ...

Vertex Pharmaceuticals has a dominant Cystic fibrosis franchise and plans to launch five new products by 2028, including a next-generation CF drug and a non-opioid pain management drug. VRTX stock has ...

Jim Cramer labels Vertex Pharmaceuticals a buy, citing its impactful mission. Analysts project a 22.33% upside for Vertex stock, despite current bearish momentum. Memorial Day Special: Access your ...

Despite commanding over 90% of its revenue from its cystic fibrosis drug franchise, Vertex has been unable to fend off investor skepticism. In 2024, the company made waves with CASGEVY, the first gene ...